Adamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson’s Disease and Movement Disorders Congress
February 28, 2017 08:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of additional data from EASE LID 2, its Phase 3 open-label,...